Pfizer, Inc.'s pain medication drug, Celebrex, has been linked to increased risks of heart attacks and strokes in high risk patients according to research published by the American Heart Association in their online journal, Circulation. Celebrex, known as a COX-2 inhibitor, is the only such product still on the market after Merck and Company pulled Vioxx from the market in 2004 and Pfizer pulled Bextra from the market in 2005 over similar concerns.
The study
The study included six clinical trials that consisted of nearly 8,000 patients who received either 200 milligrams of Celebrex twice a day or 400 milligrams of Celebrex once a day or verses a placebo. The trials concluded that that an increase of heart attacks and/or strokes was double the rate for those who were given the 200 milligram dose and triple for those given the 400 milligram dose.
Celebrex
Celebrex is prescribed to one million patients every month, according to Pfizer's Celebrex website, www.celebrex.com. The site also provides the following information:
Additional consumer information
Consumers can view additional information about Celebrex from the U.S. Food and Drug Administration's (FDA) website at: http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-ptsk.htm.